

Amendments to the Specification

On page 1, please insert the following paragraph beginning on line 3:

--This is the U.S. National Stage of International Application No. PCT/GB2003/003089, filed July 18, 2003 (published in English under PCT Article 21(2)), which in turn claims the benefit of Great Britain patent application no. 0217015.7 filed July 23, 2002.--

Please amend the paragraph beginning on page 2, line 15, as follows:

--According to an aspect of the invention there is provided a peptide comprising the amino acid sequence ARYY SAL RHY INL ITR QRT (SEQ ID NO: 2), or a variant peptide wherein said sequence is modified by addition, deletion or substitution of at least one amino acid residue, for use as a pharmaceutical agent.--

Please amend the paragraph beginning on page 2, line 23, as follows:

--According to an aspect of the invention there is provided a peptide comprising an amino acid sequence, ARYY SAL RHY INL ITR QRT (SEQ ID NO: 2), or part thereof, or variant thereof, which has been modified by addition, deletion or substitution of at least one amino acid residue, wherein said peptide has cell-cycle inhibitory activity, for the manufacture of a medicament for use in the treatment of diseases or conditions which would benefit from the inhibition of cell division.--

Please amend the paragraphs beginning on page 5, line 14, as follows:

--In a preferred embodiment of the invention said peptide comprises an amino acid sequence, or part thereof, consisting of the sequence ARYY SAL RHY INL ITR QRT (SEQ ID NO: 2). Preferably said peptide is a peptide consisting of the sequence ARYY SAL RHY INL ITR QRT (SEQ ID NO: 2).

In a further preferred embodiment of the invention said peptide is a fragment ARYY SAL RHY INL ITR QRT (SEQ ID NO: 2). Preferably said fragment is at least 3 amino acid residues in length, 4 amino acid residues in length, 5 amino acid residues in length or 6 amino acid residues in length, 7 amino acids in length, 8 amino acids in length, 9 amino acids in length, 10, amino acids in length, 11 amino acids in length, 12 amino acids in length, 13 amino acids in length, 14 amino acids in length, 15 amino acids in length, 16 amino acids in length, 17 amino acids in length, or 18 amino acids in length.--

Please amend the paragraph beginning on page 18, line 5, as follows:

-- Figure 6 is the (a) DNA (SEQ ID NO: 1) and (b) amino acid sequence (SEQ ID NO: 2) of peptide Y.--

Please insert the Abstract, submitted herewith on a separate page, as page 28 at the end of the application.

Please include the enclosed sequence listing as part of the specification.